Abstract
Apelin was identified as natural ligand for APJ, a G protein-coupled receptor. APJ is expressed in spinal cord and dorsal root ganglion. This study was designed to investigate the effects and mechanisms of intrathecally (i.t.) administered apelin-13 on nociceptive response in formalin test and tail-flick test. In formalin test, i.t. injection of apelin-13 (0.3—3 nmol/mouse) had no effect on the nociceptive response in either acute phase (0— 10 min) or interphase (10—20 min), but significantly produced hyperalgesic effect in late phase (20—30 min) at the dose of 3 nmol/mouse. The APJ receptor antagonist apelin-13(F13A) and GABAA receptor antagonist bicuculline methiodide, but not opioid receptor antagonist naloxone, significantly blocked the hyperalgesia caused by apelin-13 in late phase, indicating that i.t. apelin-13- induced hyperalgesia was mediated by APJ and GABAA receptor, rather than opioid receptor. However, in tail-flick test, i.t. injected apelin-13 (1 and 3 nmol/mouse) induced a significant antinociceptive effect, which was significantly antagonized by apelin-13(F13A) and naloxone, suggesting APJ and opioid receptor were involved in the antinociception of spinal apelin-13.
Keywords: Apelin-13, APJ, formalin test, GABA, mice, opioid, tail-flick test.
Protein & Peptide Letters
Title:Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice
Volume: 20 Issue: 8
Author(s): Shuang- Yu Lv, Yan Jie Yang, Shangyu Hong, Ning- Bo Wang, Yao- Jun Qin, Wei- Xin Li and Qiang Chen
Affiliation:
Keywords: Apelin-13, APJ, formalin test, GABA, mice, opioid, tail-flick test.
Abstract: Apelin was identified as natural ligand for APJ, a G protein-coupled receptor. APJ is expressed in spinal cord and dorsal root ganglion. This study was designed to investigate the effects and mechanisms of intrathecally (i.t.) administered apelin-13 on nociceptive response in formalin test and tail-flick test. In formalin test, i.t. injection of apelin-13 (0.3—3 nmol/mouse) had no effect on the nociceptive response in either acute phase (0— 10 min) or interphase (10—20 min), but significantly produced hyperalgesic effect in late phase (20—30 min) at the dose of 3 nmol/mouse. The APJ receptor antagonist apelin-13(F13A) and GABAA receptor antagonist bicuculline methiodide, but not opioid receptor antagonist naloxone, significantly blocked the hyperalgesia caused by apelin-13 in late phase, indicating that i.t. apelin-13- induced hyperalgesia was mediated by APJ and GABAA receptor, rather than opioid receptor. However, in tail-flick test, i.t. injected apelin-13 (1 and 3 nmol/mouse) induced a significant antinociceptive effect, which was significantly antagonized by apelin-13(F13A) and naloxone, suggesting APJ and opioid receptor were involved in the antinociception of spinal apelin-13.
Export Options
About this article
Cite this article as:
Lv Yu Shuang-, Yang Jie Yan, Hong Shangyu, Wang Bo Ning-, Qin Jun Yao-, Li Xin Wei- and Chen Qiang, Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice, Protein & Peptide Letters 2013; 20 (8) . https://dx.doi.org/10.2174/0929866511320080010
DOI https://dx.doi.org/10.2174/0929866511320080010 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioactive Peptides in Preventative Healthcare: An Overview of Bioactivities and Suggested Methods to Assess Potential Applications
Current Pharmaceutical Design The Relationship Between 24-Hour Indicators and Mortality in Patients with Exertional Heat Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets Treatment of Inflammatory and Paraproteinemic Neuropathies
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Pharmacological Manipulation of Peripheral Vascular Resistance in Single Ventricle Patients (Stages I, II, and III of Palliation)
Current Vascular Pharmacology Effects of Statins on Blood Pressure: A Review of the Experimental and Clinical Evidence.
Current Vascular Pharmacology The Beneficial Effects of Sulfur-containing Amino Acids on Cisplatininduced Cardiotoxicity and Neurotoxicity in Rodents
Current Medicinal Chemistry Dopamine and Vascular Dynamics Control: Present Status and Future Perspectives
Current Neurovascular Research Pulmonary Embolism Response Team (PERT) - A New Paradigm for the Treatment of Pulmonary Embolism
Current Pharmaceutical Design Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs
Current Topics in Medicinal Chemistry Enantioselective Transfer Reaction of Phenyl to Aldehydes Using LProline- Derived Amino Alcohols as Chiral Ligands
Letters in Organic Chemistry Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension
Current Pharmaceutical Design Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Drug-Induced Hypokalaemia
Current Drug Safety Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: A Review
Current Drug Safety Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews